The South America Non Alcoholic Steatohepatitis Biomarkers Market is witnessing gradual development as healthcare providers, research organizations, and pharmaceutical companies focus on improving the diagnosis and monitoring of liver diseases. According to Market Research Future, the market was valued at USD 15.0 million in 2024 and is projected to reach USD 19.39 million by 2035, expanding at a CAGR of 2.36% during 2025–2035.
One of the key factors influencing the market is the rising prevalence of obesity and metabolic disorders across South America. Changes in dietary habits and lifestyles are contributing to the increasing incidence of non-alcoholic fatty liver disease (NAFLD), which can progress to non-alcoholic steatohepatitis (NASH). This trend is increasing the need for reliable biomarkers that can support early disease identification and monitoring.
Advancements in biomarker research are creating additional opportunities. Researchers are investigating biological indicators associated with liver inflammation, fibrosis, oxidative stress, and apoptosis. These developments may improve the accuracy of disease assessment while supporting the development of less invasive diagnostic approaches.
The market is segmented into hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others. Hepatic fibrosis biomarkers represent a dominant category because fibrosis assessment is important for understanding liver damage. Serum biomarkers are also gaining attention because blood-based testing can provide a practical option for monitoring disease progression.
Diagnostic centres represent a major end-user segment in the region due to their specialized testing capabilities. Hospitals and clinics are also expected to experience increasing demand as healthcare providers adopt advanced diagnostic technologies. Pharmaceutical companies and CROs are investing in biomarker research to support drug development, clinical trials, and personalized medicine initiatives.
Brazil represents an important market within South America, supported by its large population, rising obesity rates, growing awareness of liver diseases, and improving healthcare infrastructure. Mexico and Argentina also offer opportunities as healthcare investments and interest in innovative diagnostic solutions increase.
Looking ahead, the market could benefit from greater government support, research funding, technological innovation, and collaboration between pharmaceutical companies and healthcare organizations. AI-powered diagnostics and point-of-care testing may further contribute to the development of NASH biomarker applications across South America.
Strengthen your strategy with data-backed research insights:
US Orthopedic Devices Market Outlook
France Medical Device Market Analysis
Atrial Fibrillation Market Distribution
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek